Skip to main content

Kyle Bauser

Stock Analyst at Roth Capital

Total Price Targets
6
Stocks Covered
5
Sectors
Healthcare
Most Recent
Dec 3, 2025

Notable Calls (Last 12 Months)

Most Bullish

  • SPRY+256.5%
    ARS Pharmaceuticals, Inc.
    $30.00 targetNov 4, 2025
  • MBOT+148.9%
    Microbot Medical Inc.
    $5.50 targetDec 3, 2025
  • IRMD+17.8%
    IRadimed Corporation
    $90.00 targetOct 31, 2025

Most Bearish

  • IRMD+16.5%
    IRadimed Corporation
    $98.00 targetNov 3, 2025
  • IRMD+17.8%
    IRadimed Corporation
    $90.00 targetOct 31, 2025
  • MBOT+148.9%
    Microbot Medical Inc.
    $5.50 targetDec 3, 2025

Stocks Covered by Kyle Bauser

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
MBOTMicrobot Medical Inc.$5.50$2.08+163.8%1Dec 3, 2025
SPRYARS Pharmaceuticals, Inc.$30.00$8.56+250.5%1Nov 4, 2025
IRMDIRadimed Corporation$98.00$86.51+13.3%2Nov 3, 2025
LFMDLifeMD, Inc.$12.00$4.99+140.7%1Oct 14, 2024
INSPInspire Medical Systems, Inc.$266.00$57.23+364.8%1Apr 29, 2021

Recent Activity

  • Dec 3, 2025— Set$5.50price target onMBOT(Microbot Medical Inc.)
  • Nov 4, 2025— Set$30.00price target onSPRY(ARS Pharmaceuticals, Inc.)
  • Nov 3, 2025— Set$98.00price target onIRMD(IRadimed Corporation)
  • Oct 31, 2025— Set$90.00price target onIRMD(IRadimed Corporation)
  • Oct 14, 2024— Set$12.00price target onLFMD(LifeMD, Inc.)
  • Apr 29, 2021— Set$266.00price target onINSP(Inspire Medical Systems, Inc.)

Frequently Asked Questions

Who is Kyle Bauser?

Kyle Bauser is a stock analyst at Roth Capital covering 5 stocks primarily in Healthcare. They have issued 6 price targets since Apr 29, 2021.

What stocks does Kyle Bauser cover?

Kyle Bauser currently covers 5 stocks, including IRMD, MBOT, SPRY, LFMD, INSP.

What is Kyle Bauser's latest price target?

Kyle Bauser's most recent price target was $5.50 on MBOT (Microbot Medical Inc.), set on Dec 3, 2025.

What is Kyle Bauser's highest price target?

Kyle Bauser's highest issued price target is $266.00 on INSP, set on Apr 29, 2021.

Coverage based on publicly published price targets. Not investment advice.